Alnylam Pharmaceuticalsvs.Moderna
ALNY vs MRNA · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Alnylam Pharmaceuticals is about 1.2× larger than Moderna by market cap; year to date, Moderna leads (+371.0% vs −40.6%).
Side by side
| ALNY | MRNA | |
|---|---|---|
| Market cap | $30.4B | $25.2B |
| Price | $240.08 | $158.83 |
| Today | +1.7% | +14.4% |
| Return YTD | −40.6% | +371.0% |
| Return 1Y | −48.1% | +412.1% |
| P/E | 37.6 | — |
| P/S | 6.3 | 11.3 |
| P/B | 22.4 | 3.7 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Alnylam PharmaceuticalsALNY
Turns RNA interference into drugs, mostly for rare and cardiovascular disease.
Full ALNY profile →ModernaMRNA
Built on mRNA, the technology behind its covid vaccine. The pipeline pushes the same platform into further vaccines and into oncology.
Full MRNA profile →More ALNY & MRNA comparisons
Other head-to-heads in the Biotech & innovation segment.
See where ALNY and MRNA sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →